UBS analyst Eliana Merle upgraded CureVac to Buy from Neutral with an $18 price target.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CVAC:
UBS analyst Eliana Merle upgraded CureVac to Buy from Neutral with an $18 price target.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CVAC: